Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Anteo Diagnostics Ltd

Healthcare AU ADO

0.011AUD
-0.002(15.38%)

Last update at 2025-06-20T06:10:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.0070.04
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap32.46M
  • Volume2679681
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.35405M
  • Revenue TTM-0.54539M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.54539M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -12.65426M -10.71681M -6.21558M -3.12656M -3.29684M
Minority interest - - - - -
Net income -12.65426M -10.71681M -6.21558M -3.12656M -2.96960M
Selling general administrative 5.14M 5.75M 3.37M 1.72M 1.74M
Selling and marketing expenses 1.74M 1.98M 1.34M 0.30M 0.16M
Gross profit 0.37M 0.76M 0.90M 0.30M 0.15M
Reconciled depreciation 1.00M 0.61M 0.44M 0.42M 0.19M
Ebit -10.79134M -13.33783M -8.17192M -4.52229M -3.62408M
Ebitda -9.79261M -12.72948M -7.73528M -4.09930M -3.43686M
Depreciation and amortization 1.00M 0.61M 0.44M 0.42M 0.19M
Non operating income net other - - - - -
Operating income -10.13416M -10.71959M -6.22050M -3.13274M -3.62408M
Other operating expenses 13.06M 11.48M 7.12M 4.40M 3.77M
Interest expense - 0.00279M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.04M 0.00279M 0.00492M 0.00618M 0.01M
Net interest income 0.00929M 0.00279M 0.00492M 0.00618M 0.01M
Extraordinary items 0.00000M 0.00000M - 0.00000M 0.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.52M -0.61113M -0.44156M -0.42917M -0.32724M
Total revenue 0.37M 0.76M 0.90M 0.30M 0.15M
Total operating expenses 13.72M 14.10M 9.07M 4.82M 3.77M
Cost of revenue - - - - -
Total other income expense net 0.66M 2.01M 1.51M 0.97M 0.33M
Discontinued operations - - - - -
Net income from continuing ops -12.65426M -10.71681M -6.21558M -3.12656M -3.29684M
Net income applicable to common shares -12.65426M -10.71681M -6.21558M -3.12656M -3.29684M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 9.38M 5.36M 15.26M 23.68M 3.91M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.22M 0.22M 0.25M 0.15M 0.09M
Total liab 4.08M 2.99M 2.91M 2.56M 0.70M
Total stockholder equity 5.31M 2.38M 12.36M 21.11M 3.21M
Deferred long term liab - - - - -
Other current liab 0.65M 1.27M 0.91M 0.69M 0.56M
Common stock 99.82M 89.30M 87.45M 86.21M 64.29M
Capital stock - 89.30M 87.45M 86.21M 64.29M
Retained earnings -99.89660M -91.01608M -78.36182M -67.64501M -61.42943M
Other liab - 0.52M 0.52M 0.47M 0.08M
Good will - - - - -
Other assets - 0.00000M 0.42M - -
Cash 5.03M 2.72M 10.10M 21.39M 3.21M
Cash and equivalents - - - - -
Total current liabilities 1.79M 1.80M 1.62M 1.08M 0.62M
Current deferred revenue - -0.64759M -0.25754M -0.27717M -0.13487M
Net debt -2.69091M -1.41362M -9.06975M -20.11023M -3.07967M
Short term debt 0.63M 0.65M 0.26M 0.28M 0.13M
Short long term debt - - - - -
Short long term debt total 2.33M 1.31M 1.03M 1.28M 0.13M
Other stockholder equity - 4.09M -9.09259M -18.56389M -2.86227M
Property plant equipment - 2.22M 4.02M 1.89M 0.53M
Total current assets 5.45M 3.14M 10.83M 21.79M 3.38M
Long term investments - - - - -
Net tangible assets - 2.38M 12.36M 21.11M 3.21M
Short term investments - - - - -
Net receivables 0.21M 0.20M 0.47M 0.24M 0.07M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.52M 0.53M 0.70M 0.39M 0.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.39M 4.09M 3.26M 2.55M 0.35M
Additional paid in capital - - - - -
Common stock total equity - - - - 64.29M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -2.22024M 0.42M -1.88642M -0.53057M
Deferred long term asset charges - - - - -
Non current assets total 3.93M 2.22M 4.44M 1.89M 0.53M
Capital lease obligations - 1.31M 1.03M 1.28M 0.13M
Long term debt total - 0.66M 0.78M 1.00M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.69083M -3.11796M -0.21307M -0.27045M -0.07823M
Change to liabilities -0.15606M 0.36M 0.38M -0.05351M -0.04673M
Total cashflows from investing activities -0.69083M -3.11796M -0.21307M -0.27045M -0.07823M
Net borrowings -0.45655M -0.27603M -0.22993M -0.24069M -0.24069M
Total cash from financing activities 1.39M 0.48M 22.94M 1.71M 3.37M
Change to operating activities 0.07M 0.20M 0.07M 0.10M -0.08063M
Net income -12.65426M -10.71681M -6.21558M -3.12656M -2.96960M
Change in cash -7.38321M -11.28906M 18.18M -1.06158M 0.95M
Begin period cash flow 10.10M 21.39M 3.21M 4.28M 3.33M
End period cash flow 2.72M 10.10M 21.39M 3.21M 4.28M
Total cash from operating activities -8.08317M -8.68891M -4.54930M -2.50190M -2.34353M
Issuance of capital stock 1.85M 0.76M 24.20M 2.16M 3.65M
Depreciation 1.00M 0.61M 0.44M 0.42M 0.19M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.27M -0.22735M -0.23292M 0.00198M 0.72M
Sale purchase of stock - 0.76M -1.02605M -0.20597M -0.28226M
Other cashflows from financing activities -0.45655M -0.27603M -0.22993M -0.24069M -0.07823M
Change to netincome 3.39M 1.24M 1.01M 0.15M 0.17M
Capital expenditures 0.69M 3.12M 0.21M 0.27M 0.08M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.27M -0.22735M -0.23292M 0.00198M 0.88M
Stock based compensation 0.83M 1.20M 1.01M 0.15M -
Other non cash items 3.57M 1.42M 1.23M 0.20M 3.11M
Free cash flow -8.77400M -11.80687M -4.76237M -2.77236M -0.07823M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADO
Anteo Diagnostics Ltd		 -0.002 15.38% 0.01 - - 82.26 3.51 29.61 -4.5341
CSL
CSL Ltd		 1.50 0.63% 240.21 28.64 32.15 7.65 4.04 5.81 18.03
TLX
Telix Pharmaceuticals Ltd		 -0.08 0.32% 24.92 166.67 57.47 10.68 14.73 10.52 89.03
MSB
Mesoblast Ltd		 -0.03 1.80% 1.64 - 454.55 367.78 2.98 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.10 0.80% 12.54 11.61 75.76 7.37 4.49 6.61 8.03

Reports Covered

Stock Research & News

View All

Profile

AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, North America, and Latin America. Its products include AnteoBind, s an activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit , a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micron, Particle-based assay development and bioseparation; AnteoBind Biosensor, a planar solid phase assay development; Activation Kit Multiplex Microspheres, an immunoassay development; and Nano Kit, a nanoparticle-based lateral flow assay development and bioseparation. The company also offers AnteoX, an additive that reinforces battery binders that enhance performance of silicon containing anodes; and Ultranode, an ultra-high silicon anode design to offer high performance for lithium-ion batteries. In addition, it provides contract services. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.

Anteo Diagnostics Ltd

Brisbane Technology Park, Eight Mile Plains, QLD, Australia, 4113

Key Executives

Name Title Year Born
Mr. Timothy J. Pritchard B.Bus, CPA, GIA (Cert), MCom, MIT CFO & Company Sec. NA
Mr. Christopher Parker Chair of the Clinical Advisory Board & Non Exec. Director NA
Mr. David John Radford BSc (Hons), MAICD, MBA MD, CEO & Director NA
Dr. N. Joe Maeji B.Sc., Ph.D. Founder & Chief Scientific Officer NA
Ms. Katrina Byrne Chief Operating Officer NA
Ms. Friederike Graser Communications Mang. NA
Dr. Charlie Huang B.Sc., Ph.D. Chief Innovation Officer NA
Mr. Selahattin Guldu Exec. VP of Commercial Banking NA
Mr. Manuel Wieser Head of Energy NA
Mr. Pierre Nathie Head of Products & Services ? Life Sciences NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.